1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        North America Pulmonary Arterial Hypertension Market – By Drugs

1.3.2        North America Pulmonary Arterial Hypertension Market – By Type

1.3.3        North America Pulmonary Arterial Hypertension Market – By Route of Administration

1.3.4        North America Pulmonary Arterial Hypertension Market – By Distribution Channel

1.3.5        North America Pulmonary Arterial Hypertension Market – By Country

2.           North America Pulmonary Arterial Hypertension Market – Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           North America Pulmonary Arterial Hypertension Market – Market Landscape

4.1         Overview

4.2         North America PEST Analysis

4.3         Experts Opinion

5.           North America Pulmonary Arterial Hypertension Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Growing Incidence of Pulmonary Arterial Hypertension

5.1.2        Rising Approvals of Pulmonary Arterial Hypertension Drugs

5.2         Market Restraints

5.2.1        Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension

5.3         Market Opportunities

5.3.1        Availability of Generics at Affordable Costs Due to Growing Patent Expiration

5.3.2        Drugs Patents Expiration Data

5.4         Future Trend

5.4.1        Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension

5.5         Impact analysis

6.           Pulmonary Arterial Hypertension Market – North America Analysis

6.1         North America Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis

7.           North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Drugs

7.1         Overview

7.2         North America Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)

7.3         Endothelin Receptor Antagonists (ERAs)

7.3.1        Overview

7.3.2        Endothelin Receptor Antagonists (ERAs): North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

7.4         Prostacyclin and Prostacyclin Analogs

7.4.1        Overview

7.4.2        Prostacyclin and Prostacyclin Analogs: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

7.5         SGC Stimulators

7.5.1        Overview

7.5.2        sGC Stimulators: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

7.6         Pde-5 Dipsticks

7.6.1        Overview

7.6.2        Pde-5 Dipsticks: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

8.           North America Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 – by Type

8.1         Overview

8.2         North America Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)

8.3         Branded

8.3.1        Overview

8.3.2        Branded: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

8.4         Generics

8.4.1        Overview

8.4.2        Generics: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

9.           North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Route of Administration

9.1         Overview

9.2         North America Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)

9.3         Oral

9.3.1        Overview

9.3.2        Oral: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

9.4         Intravenous/ Subcutaneous

9.4.1        Overview

9.4.2        Intravenous/ Subcutaneous: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

9.5         Inhalational

9.5.1        Overview

9.5.2        Inhalational: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10.        North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – by Distribution Channel

10.1      Overview

10.2      North America Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)

10.3      Hospital Pharmacies and Clinics

10.3.1     Overview

10.3.2     Hospital Pharmacies and Clinics: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10.4      Online Pharmacies

10.4.1     Overview

10.4.2     Online Pharmacies: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

10.5      Retail Pharmacies

10.5.1     Overview

10.5.2     Retail Pharmacies: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.        North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 – Country Analysis

11.1      Overview

11.1.1.1       US: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.1       Overview

11.1.1.1.2       US: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.3       US: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.1.1.1.4       US: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.1.1.1.5       US: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.1.6       US: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.1.1.2       Canada: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.1       Overview

11.1.1.2.2       Canada: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.3       Canada: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.1.1.2.4       Canada: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.1.1.2.5       Canada: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.2.6       Canada: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

11.1.1.3       Mexico: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.1       Overview

11.1.1.3.2       Mexico: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.3       Mexico: Pulmonary Arterial Hypertension Market, by Drugs, 2019–2028 (US$ Million)

11.1.1.3.4       Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019–2028 (US$ Million)

11.1.1.3.5       Mexico: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.3.6       Mexico: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019–2028 (US$ Million)

12.        North America Pulmonary Arterial Hypertension Market – Industry Landscape

12.1      Overview

12.2      Organic Developments

12.2.1     Overview

12.3      Inorganic Developments

12.3.1     Overview

13.        Company Profiles

13.1      Johnson & Johnson

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      Gilead Sciences Inc

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      United Therapeutics Corp

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      Bayer AG

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Aerami Therapeutics Holdings Inc

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

13.6      Novartis AG

13.6.1     Key Facts

13.6.2     Business Description

13.6.3     Products and Services

13.6.4     Financial Overview

13.6.5     SWOT Analysis

13.6.6     Key Developments

13.7      GSK Plc

13.7.1     Key Facts

13.7.2     Business Description

13.7.3     Products and Services

13.7.4     Financial Overview

13.7.5     SWOT Analysis

13.7.6     Key Developments

13.8      Teva Pharmaceutical Industries Ltd

13.8.1     Key Facts

13.8.2     Business Description

13.8.3     Products and Services

13.8.4     Financial Overview

13.8.5     SWOT Analysis

13.8.6     Key Developments

13.9      Lupin Ltd

13.9.1     Key Facts

13.9.2     Business Description

13.9.3     Products and Services

13.9.4     Financial Overview

13.9.5     SWOT Analysis

13.9.6     Key Developments

13.10   Pfizer Inc

13.10.1  Key Facts

13.10.2  Business Description

13.10.3  Products and Services

13.10.4  Financial Overview

13.10.5  SWOT Analysis

13.10.6  Key Developments

14.        Appendix

14.1      About The Insight Partners

14.2      Glossary of Terms

LIST OF TABLES

Table 1.             Drugs Patents Expiration Data

Table 2.             North America Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 3.             US Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 4.             US Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 5.             US Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 6.             US Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 7.             Canada Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 8.             Canada Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 9.             Canada Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 10.          Canada Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Mexico Pulmonary Arterial Hypertension Market, by Drugs – Revenue and Forecast to 2028 (US$ Million)

Table 12.          Mexico Pulmonary Arterial Hypertension Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 13.          Mexico Pulmonary Arterial Hypertension Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Mexico Pulmonary Arterial Hypertension Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 15.          Organic Developments in the North America pulmonary arterial hypertension market

Table 16.          Inorganic Developments in the North America pulmonary arterial hypertension market

Table 17.          Glossary of Terms

LIST OF FIGURES

Figure 1.           North America Pulmonary Arterial Hypertension Market Segmentation

Figure 2.           North America Pulmonary Arterial Hypertension Market – By Country

Figure 3.           North America Pulmonary Arterial Hypertension Market Overview

Figure 4.           Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of the North America Pulmonary Arterial Hypertension Market

Figure 5.           US to Show Significant Growth During Forecast Period

Figure 6.           North America: PEST Analysis

Figure 7.           Experts Opinion

Figure 8.           North America Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint

Figure 9.           North America Pulmonary Arterial Hypertension Market– Revenue Forecast and Analysis – 2020 - 2028

Figure 10.        North America Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)

Figure 11.        Endothelin Receptor Antagonists (ERAs): North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12.        Prostacyclin and Prostacyclin Analogs: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.        sGC Stimulators: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.        Pde-5 Dipsticks: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15.        North America Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)

Figure 16.        Branded: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        Generics: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.        North America Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)

Figure 19.        Oral: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20.        Intravenous/ Subcutaneous: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.        Inhalational: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.        North America Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)

Figure 23.        Hospital Pharmacies and Clinics: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24.        Online Pharmacies: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.        Retail Pharmacies: North America Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.        North America: Pulmonary Arterial Hypertension Market, by Key Country – Revenue (2021) (US$ Million)

Figure 27.        North America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)

Figure 28.        US: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.        Canada: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30.        Mexico: Pulmonary Arterial Hypertension Market – Revenue and Forecast to 2028 (US$ Million)